SCHEMBL20061329

SCHEMBL20061329

Cc1cc2cc(F)ccc2nc1[C@H](C)N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.47
TSHR P16473 1/20 0.38
HTR2C P28335 5/20 0.37
HTR2A P28223 4/20 0.37
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
PIK3CD O00329 1/20 0.34
PIK3CG P48736 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2A6 P11509 1/20 0.34
AXL P30530 1/20 0.34
GFER P55789 1/20 0.34
MBNL1 Q9NR56 1/20 0.34
TYMS P04818 1/20 0.34
MPO P05164 1/20 0.34
NPY1R P25929 1/20 0.33
NPY2R P49146 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9251597 0.75 BACE1 (0.44) BACE1TSHRPDE3BPDE3ACYP1A2
SCHEMBL12827021 0.74 TSHR (0.51) BACE1TSHRPDE3BPDE3AMBNL1
SCHEMBL3778706 0.73 PIK3CD (0.58) BACE1PIK3CDPIK3CG
SCHEMBL20061336 0.73 PIK3CD (0.58) BACE1PIK3CDPIK3CG
SCHEMBL27746521 0.72 TDP1 (0.58) BACE1TSHRPDE3BPDE3ACYP1A2
SCHEMBL28563970 0.71 HTT (0.49) MEN1KMT2A
SCHEMBL20067907 0.71 HTT (0.49) MEN1KMT2A
SCHEMBL384813 0.69 CYP1A2 (0.63) BACE1TSHRCYP1A2CYP2A6NPC1
SCHEMBL17942618 0.68 BACE1 (0.53) BACE1TSHRPDE3BPDE3AAXL
SCHEMBL2609295 0.68 BACE1 (0.53) BACE1TSHRHTR2CHTR2APDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180105527-A1 HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180105527-A1 HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT WEE2, WEE1, ITK BACE1 2870/4885TSHR 4274/4885HTR2C 4084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.